Edition:
United Kingdom

Acasti Pharma Inc (ACST.OQ)

ACST.OQ on NASDAQ Stock Exchange Capital Market

1.04USD
16 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.04
Open
$1.04
Day's High
$1.04
Day's Low
$1.02
Volume
5,577
Avg. Vol
130,998
52-wk High
$3.34
52-wk Low
$0.85

Chart for

About

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Acasti Pharma Q3 ‍net Loss 2017 Was $0.40 Per Share​

* ACASTI PHARMA REPORTS THIRD QUARTER FY 2018 FINANCIAL RESULTS

13 Feb 2018

BRIEF-Acasti Pharma grants Chinese pharma co exclusive license to commercialize CaPre in China​

* Acasti Pharma Inc - ‍clarifies term of proposed strategic partnership with China pharmaceutical company​

22 Nov 2017

BRIEF-Acasti Pharma ‍enters into non-binding agreement with China-based pharma

* Acasti Pharma Inc - ‍entered into a non-binding term sheet with a China-based pharmaceutical company​

20 Nov 2017

BRIEF-Acasti Pharma says is offering 11.7 mln common shares‍​

* Says it is offering 11.7 million common shares‍​ - SEC Filing Source text: (http://bit.ly/2mBXlkS) Further company coverage:

16 Nov 2017

BRIEF-Acasti Pharma reports Q2 loss per share C‍$0.31​

* Acasti Pharma reports second quarter FY 2018 financial results

13 Nov 2017

BRIEF-Acasti Pharma files for offering of up to $17.25 mln of common stock‍​

* Acasti Pharma Inc files for offering of up to $17.25 million of common stock‍​ - sec filing‍​ Source text : http://bit.ly/2yN6Pf7 Further company coverage:

29 Sep 2017

Earnings vs. Estimates